Updates on Molecular Tests & PCR

Catriona Halliday PhD
Clinical Mycology Reference Laboratory – ICPMR, NSWHP
Westmead Hospital, Australia

Presented at MMTN August 4–6 2025.
Copyright of speaker. All rights reserved.

Disclosures

- The speaker declares no conflict of interest.

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

Culture Independent Diagnosis

- Fungal biomarkers – surrogate markers of IFD
  1. Fungal DNA – PCR based assays
  2. Fungal antigens – β-D- glucan, *Aspergillus* galactomannan

- Useful adjunct for early diagnosis

- Incorporated into care pathways & diagnostic algorithms
  - Steward & monitor antifungal therapies
  - Predict treatment outcomes
  - EORTC/MSGERC consensus definitions (Donnelly, CID, 2020)

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

MMTN
MEDICAL MYCOLOGY
TRAINING NETWORK

PCR-based Assay Strategy

1. Rule out particular IFD
   - Screening test in asymptomatic patients – Utilizes a high NPV
   - Pre-emptively diagnose in high-risk patient 8–10% incidence (not cost effective in patients with lower incidences)
   - Requires frequent testing (e.g., blood)
   - Ideally TAT 24-48h; short enough to impact patient management
2. Support in a diagnosis ("Upgrade" category of IFD)
   - Enable a definite diagnosis in patients with signs and symptoms of infection
   - Pre-test probability increased

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

Kidd *et al.*, *Front Microbiol*, 2020; Barnes et al., *Med Mycol.*, 2018

Aspergillus PCR for Diagnosis

- Accepted as mycological criterion for probable IA
  - Blood (serum, plasma, whole blood); ≥2 consecutive PCR +ve tests
  - BAL fluids; ≥2 duplicate PCR +ve results
  - ≥1 PCR +ve blood (serum/plasma/whole blood) AND 1 PCR +ve BAL fluid

(Donnelly et al, *CID* 2020; White et al *CID* 2021)

- Provides robust diagnostic test for:
  - Screening patients at moderate-high risk of IA
  - Confirming diagnosis of *Aspergillus* infection

(Cruciani et al. *Cochrane Databases Syst Rev* 2019, 9:CD009551)

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

Aspergillus PCR Technical Considerations

- Specimen volume, nucleic acid extraction protocol & elution volume critical to PCR assay performance
  - ≥3 mL whole blood; ≥0.5 mL serum/plasma
  - Mechanical disruption of cell wall required for efficient NA extraction
  - Elution volume ≤100 µL

- PCR assay not rate-limiting to success
  - Multi-copy gene target enhances sensitivity (28S rRNA or ITS)
  - Pan-*Aspergillus* target preferred
  - Recommend PCR testing in duplicate
  - qPCR minimises contamination

Presented at MMTN August 4–6 2023
Copyright of speaker. All rights reserved.

Commercial *Aspergillus* PCR Assays

- Numerous commercial assays available (Rath & Steinmann, Front Microbiol, 2018)
  - Provide standardised methodology & independent QC of reagents
  - Significantly lower sensitivities in serum vs respiratory specimens
  - Limited data on clinical utility & head-to-head comparisons
  - Some assays detect prevalent *cyp51A* gene mutations conferring azole resistance

Presented at MMTN August 4–6 2023
Copyright of speaker. All rights reserved.

Aspergillus PCR

- Negative PCR result can exclude IA in antifungal drug naïve patients
- Positive PCR result is useful for diagnosis
  - Positive result from BALF cannot distinguish colonisation from IA (PPV 72%)

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

Detection of Azole Resistance by PCR

- Performance of 3 commercial assays evaluated on BAL (n=103)
  - MycoGENIE® *Aspergillus fumigatus* real-time PCR kit (Adamtech)
  - Fungiplex® *Aspergillus* Azole-R IVD real time PCR kit (Bruker Daltonik)
  - AsperGenius® (PathoNostics)

Probable IPA (n=11) vs possible (n=51) /no IPA (n=41)

Kit	Sensitivity	Specificity	PPV	NPV
MycoGENIE®	80%	73.2%	26.7%	96.8%
Fungiplex®	60%	91%	42.9%	95.4%
AsperGenius®	63.6%	96.7%	70%	95.7%

- Only 1 azole-resistant isolate (TR34 mutation) detected by all three assays

Scharmann et al. *J Fungi*, 2021; Pelzer et al. *Med Mycol*, 2020

Presented at MMTN August 4–6 2023
Copyright of speaker. All rights reserved.

MMTN
MEDICAL MYCOLOGY
TRAINING NETWORK

Mucorales PCR

- Incidence of mucormycosis is increasing due to:
  - Increase in number of susceptible people
  - Change in antifungal practice
  - Improved diagnostics (PCR from culture negative tissue, BALF, serum & urine)

- Early diagnosis is key to improving survival outcomes

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

Mucorales PCR for Diagnosis

- Detection in fresh or FFPE tissue resulted in increase in diagnosed cases
  - Sensitivities of 97–100% on fresh tissue & 56–91% on FFPE

- Aids diagnosis of pulmonary mucormycosis from BALF
  - PCR +ve in all 10 patients with proven/probable disease
  - PCR earliest and/or only biological evidence of disease in 4 patients
  - 6 of 24 patients (25%) co-infected with *Aspergillus*-Mucorales
  - Supports inclusion in diagnostic approach despite difficulty obtaining BALF

(Scherer et al, *JCM* 2018)

Presented at MMTN August 4–6 2023
Copyright of speaker. All rights reserved.

Mucorales PCR for Screening

MODIMUCOR Prospective trial (Millon et al, *CID*, 2022)

- Assess performance of serum Mucorales qPCR for early diagnosis of mucormycosis
- 232 patients enrolled prospectively, 2x weekly screening of serum
- qPCR targets *Lichtheimia*, *Rhizomucor* & *Mucor/Rhizopus*
- Sensitivity, 85.2%; specificity, 89.8%, PLRz, 8.3; NLR, 0.17
- PCR +ve from serum 4 days before mycological/histopathological examination, 1 day before 1st imaging performed
- -ve PCR within 7 days of L-AMB associated with 85% lower 30-day mortality
- Argues for inclusion in EORTC/MSGERC definitions

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

Commercial Mucorales PCR Assays

	MucorGenius® Real-Time PCR	MycoGENIE® Aspergillus Species—Mucorales Species	Fungiplex® Mucorales RUO PCR Kit
Diagnostic specimens	Bronchoalveolar lavage Biopsy samples, paraffin embedded Serum	Serum Biopsies Lower respiratory tract samples	Not specified
Species detected	*Rhizopus* spp. *Mucor* spp. *Lichtheimia* spp. *Cunninghamella* spp. *Rhizomucor* spp.	*Rh. Pusillus* *M. indicus* *M.circinelloides* *M.plombeus* *R. arrhizus* *R. stolonifera* *L. corymbifera* *L. glauca* *C. bertholletiae* *Mycotypha* sp.	*Rhizopus* spp. *Lichtheimia* spp. *Cunninghamella* spp. *Rhizomucor* spp. *Mucor* spp. *Actinomucor* spp. *Apophysomyces* spp. *Saksenaea* spp. *Syncephalastrum* spp.
Manufacturer	PathoNostics	Ademtech	Bruker

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

Dannaoui, *J Fungi* 2022, 8, 457

MucorGenius® Mucorales RUO

- Detect clinically relevant Mucorales species in ~3 h
- BALF, tissue (fresh & FFPE), serum
- Lacks extensive clinical validation
- Good performance. Sensitivity, 90% (9/10); specificity, 97.9%, missed case with low fungal burden (Guegan et al. *J. Infect*, 2020)
- Sensitivity on serial blood 75%, preceded microbiological diagnosis (Mercier et al. *J Fungi*, 2019)
- Lower analytical sensitivity to in-house assay & decreased detection of *Lichtheimia corymbifera* (*J Fungi* 2022, 8, 786)

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

Panfungal PCR

- Detect & identify "all" fungi from diverse specimen types
  - ITS or 28S are recommended targets
  - BLAST sequences against quality-controlled databases

- Best results from sterile specimens (not BALF)
  (Zeller et al. *J Microbiol*, 2017; Garnham et al. *Pathology*, 2020)

- Detect novel or unexpected pathogens
  - 44% (8/18) +ve with non-*Aspergillus*/*Candida* species
    (Sugaware et al. *Eur J Haematol*, 2013)

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

Panfungal PCR for Diagnosis

EORTC/MSGERC recommend use of PCR & DNA sequencing for genus/species ID from fresh/FFPE tissue

- ***ONLY*** when fungal elements seen by histopathology
- ***NOT*** recommended where fungal staining is negative
- Identification ***MUST*** be consistent with histopathological features
- Rigorous quality control (+ve, -ve & internal control)
- PCR should target fungal barcoding genes (ITS or 28S)
- Every PCR product should be sequenced
- Performed ***ONLY*** in reference centres or high-volume centres
- Fulfil criteria of PROVEN fungal disease

Presented at MMTN August 4–6 2023
Copyright of speaker. All rights reserved.

Donnelly et al *CID* 2020;71:1367 & Lockhart et al *CID* 2021;72:S109

Panfungal PCR on Tissue

- Diagnostic yield increases with pre-test probability
  - 71.3% patients with proven/probable IFD (variety of specimens)
  - <10% specimens with no fungal elements
  - Yield from biopsy specimens: 71.5% open resection; 50% core-needle; 0% FNA (Gomez et al, *CID*, 2017)

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

Panfungal PCR on Tissue

- Limited utility on histopathology negative FFPE (n=248)
  - 28% (69/248) yielded invalid result (no HBG)
  - 18% (45/248) positive histology; 49% (22/45) positive PCR; 36% (16/45) clinically significant PCR result
  - 9% (19/203) histology negative yielded positive PCR; 3% (6/203) clinically significant PCR result
  - AU$258 histopathology positive vs AU$3105 histology negative
  - Panfungal PCR on histopathology negative FFPE tissue ***NOT*** recommended (Sparks et al, *Pathology*, 2023)

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

MMTN
MEDICAL MYCOLOGY
TRAINING NETWORK

Panfungal PCR on BALF

- Interpretation difficult – Infection, colonisation or environmental contamination?
  - *Candida, Saccharomyces*, *Rhodotorula* & "mixed" most frequently detected (Trubiano et al *Med Mycol*, 2016; Rahn et al *J Med Micro*, 2016)

- Sensitivity lower in patients receiving mould-active treatment – Negative does not exclude IFD

- Diagnostic utility & costs (Garnham et al Pathology, 2020)
  - 53% (530/1,002) yielded positive; 8.5% (45/1,002) clinically significant
  - Recommend > pre-analytical stewardship – limit to high-risk (neutropenic) patients with clinical/radiological evidence of IFD

Presented at MMTN August 4-6 2023
Copyright of speaker. All rights reserved.

Pneumocystis jirovecii PCR Assays

- Increasingly used by diagnostic labs
- Detect colonisation, asymptomatic infection, sub-clinical & active infection – correlate +ve PCR with clinical, radiological & laboratory findings
  (Doyle et al, *OFID*, 2017)
  "Affords discrimination of early true disease vs rarer instances of colonisation"
- ECIL guidelines recommend real-time PCR for routine diagnosis of PCP
  (Alanio et al, *JAC*, 2016)
  - BALF best specimen (A-II)
  - Yield from BALF > induced sputum > oropharyngeal wash

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

MMTN
MEDICAL MYCOLOGY
TRAINING NETWORK

Pneumocystis jirovecii PCR Assays

- PCP qPCR incorporated into EORTC/MSGERC criteria
  - Mycological evidence of pneumocystis from BALF, IS or OW
  - Do NOT recommend threshold for positivity

- Numerous commercial assays available – excellent concordance with in-house assays (Sasso et al, *JCM*, 2016; Huh et al, *Ann Lab Med*, 2019)

- FPCRI pneumocystis working group
  - Establish consensus method
  - Assist with lab standardisation & quantification
  - Recommend SSU or mitochondrial LSU

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

Candida PCR

- Fulfils many of criteria for “ideal diagnostic test for IC”

Sensitive (<5 CFU/ml)	Multiplex capability	Rapid TAT
Minimally invasive sampling	Provides speciation	+ve before culture

- Utility not clearly defined – Use differs in different clinical contexts
- Lacks standardisation & limited validation in real-life prospective settings – FPCRI developing standards

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

Commercial *Candida* PCR Assays

Product	Manufacturer	Species Targeted
AusDiagnostics Sepsis	AusDiagnostics Pty Ltd	*C. albicans, glabrata, krusei, parapsilosis* & *tropicalis*
*Cand*ID & *Auris*ID	OlmDiagnostics	*C. albicans, dubliniensis, glabrata, krusei, parapsilosis* & *tropicalis; C. auris*
FungiPlex *Candida* & FungiPlex *Candida auris*	Bruker Daltonik	*C. albicans, dubliniensis, glabrata, krusei, parapsilosis* & *tropicalis; C. auris*
Magicplex Sepsis Real-time Test	Seegne	*C. albicans, glabrata, krusei, parapsilosis* & *tropicalis* (and *A. fumigatus*)
MycoReal *Candida*	Ingenetix	*C. albicans, dubliniensis, glabrata, krusei, lusitaniae, parapsilosis* & *tropicalis*
SeptiFast Real-time PCR	Roche Diagnostics	*C. albicans, glabrata, krusei, parapsilosis* & *tropicalis*
T2 *Candida* T2 *C. auris*	T2 Biosystems	*C. albicans/tropicalis*, *C. glabrata* cx/*krusei* and *C. parapsilosis* cx; *C. auris*

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved

Cryptococcus PCR

- Commercial assays:
  - BioFire FilmArray Meningitis/Encephalitis panel (bioMerieux)
  - AusDiagnostics Atypical Pneumonia & CSF panels
  - Limited to certain specimens (CSF & BALF)
  - Sub-optimal sensitivity due to substantial multiplexed nature
  - Cannot discriminate *C. neoformans* from *C. gattii*

- Real-time targeted PCR to detect & identify *C. neoformans* & *C. gattii* from sterile & non-sterile specimens
  (Tay et al, *J Fungi*, 2022)

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.

Cryptococcus PCR

- High resolution melt-curve analysis discriminates between 2 species (Tay et al *J Fungi*, 2022)

C. neoformans (81°C) & *C. gattii* (79°C)



Presented at MMTN August 4-6 2023
Copyright of speaker. All rights reserved.

MMTN
MEDICAL MYCOLOGY
TRAINING NETWORK

Conclusions

- Important advances in standardisation of PCR tests – incorporated into EORTC/MSGERC criteria
- PCR tests are NOT standalone tests – valuable "add on" tools which fulfil diagnostic gaps
  - Must optimise test algorithms
- MUST be interpreted in clinical context of patient & other findings
- Risk factor stratification – predict individuals at greatest risk

Presented at MMTN August 4–6 2023
Copyright of speaker. All rights reserved.

Thank you

Presented at MMTN August 4–6 2023.
Copyright of speaker. All rights reserved.